uniQure N.V — Cash Flow (NASDAQ:QURE) | MetaTrader

Open full chart

Financials

Overview Finanzbericht Statistics Dividends

Quarterly Annual

Cash from operating activities -134.83 M287.96 M-145.06 M-145.93 M-182.73 M -153.24 M Cash from investing activities -9.48 M-67.39 M-182.73 M-205.69 M162.97 M 93.13 M Cash from financing activities 7.44 M94.86 M1.45 M362.72 M-59.49 M — Free cash flow -144.31 M270.52 M-162.75 M-153.08 M-186.1 M -153.6 M

uniQure N.V

uniQure is a Dutch biopharmaceutical company which makes gene therapies. It has developed several adeno-associated virus gene therapies.

Nachrichten

uniQure: Shares Tumble On Fresh FDA Controversy - What Investors Should Know (NASDAQ:QURE)

uniQure-Quartalszahlen: Zulassungsweg für Hoffnungsträger AMT-130 im Fokus

uniQure earnings in focus as AMT-130 regulatory path looms

Stifel bewertet uniQure nach Äußerungen des FDA-Commissioners zu seltenen Krankheiten

Stifel comments on uniQure shares after FDA commissioner remarks

Uniqure Plummets As FDA's Marty Makary Disparages Rejected Rare Disease Drug

Applied Materials, Broadcom among market cap stock movers on Thursday

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Beats Revenue Estimates

UniQure-Aktie bricht nach FDA-Kommentaren zu Gentherapie-Studie ein

UniQure stock tumbles on FDA comments about gene therapy trial

uniQure: Wolfe Research nimmt Bewertung mit „Peerperform“ auf

uniQure stock initiated at Peerperform by Wolfe Research